China Universal Asset Management Company’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.7M Sell
16,003
-1,807
-10% -$268K 0.16% 101
2026
Q1
$2.35M Buy
17,810
+1,563
+10% +$207K 0.18% 97
2025
Q4
$2.3M Sell
16,247
-1,138
-7% -$165K 0.18% 98
2025
Q3
$2.44M Sell
17,385
-2,492
-13% -$338K 0.2% 96
2025
Q2
$2.5M Sell
19,877
-122
-0.6% -$14K 0.24% 87
2025
Q1
$2.21M Sell
19,999
-1,469
-7% -$186K 0.21% 98
2024
Q4
$2.93M Buy
21,468
+2,047
+11% +$253K 0.27% 76
2024
Q3
$2.24M Buy
19,421
+7,597
+64% +$1.04M 0.25% 89
2024
Q2
$1.63M Sell
11,824
-7,324
-38% -$1M 0.23% 81
2024
Q1
$2.64M Buy
19,148
+7,784
+68% +$1.06M 0.34% 64
2023
Q4
$1.5M Buy
11,364
+8,860
+354% +$1.02M 0.29% 82
2023
Q3
$282K Buy
2,504
+1,225
+96% +$129K 0.08% 130
2023
Q2
$121K Sell
1,279
-30
-2% -$2.93K 0.04% 147
2023
Q1
$132K Buy
1,309
+332
+34% +$34.5K 0.04% 125
2022
Q4
$117K Buy
977
+81
+9% +$9.49K 0.05% 117
2022
Q3
$95K Buy
+896
New +$90.9K 0.04% 111

Other funds holding NBIX

China Universal Asset Management Company's NBIX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q2 2026, selling an estimated $268K and leaving 16,003 shares worth $2.7M. The position accounts for 0.16% of the portfolio, ranked #101.

China Universal Asset Management Company first reported a position in NBIX in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.93M in Q4 2024. 262 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • China Universal Asset Management Company held 16,003 shares of Neurocrine Biosciences worth $2.7M as of Q2 2026.
  • China Universal Asset Management Company sold 1,807 Neurocrine Biosciences shares in Q2 2026, an estimated $268K.
  • Neurocrine Biosciences made up 0.16% of China Universal Asset Management Company's portfolio in Q2 2026, its #101 holding.
  • China Universal Asset Management Company first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Neurocrine Biosciences position peaked at $2.93M in Q4 2024.
  • 262 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.